White W B, Desbonnet C R, Ballow M
Department of Medicine, University of Connecticut School of Medicine, Farmington.
Am J Med. 1987 Sep;83(3):431-6. doi: 10.1016/0002-9343(87)90752-2.
Because of evidence of immunoregulatory effects of short-term administration of pooled donor gamma globulins, the effects of intravenous immune serum globulin were studied in nine adult patients with common variable hypogammaglobulinemia over a two-year period. Baseline assessment prior to immune serum globulin replacement included evaluation of B cell function, suppressor cell activity, and T cell subsets. These analyses were subsequently performed during the course of a first-year treatment period of intravenous immune serum globulin at doses of 100 to 200 mg/kg per month and a second-year trial at doses of 300 to 400 mg/kg per month. Five patients were re-evaluated following discontinuation of the intravenous immune serum globulin therapy for four months between the first and second treatment periods. During both treatment periods with intravenous immune serum globulin, suppressor cell activity increased markedly compared with baseline, and declined following discontinuation of drug therapy in the five patients. Suppressor cell activity was reversed by either irradiation of the T cell fraction or removal of the T8-positive cell fraction by flow cytometry. There was a reduction in the absolute number of total lymphocytes, the T3-positive cells (total T cells), and the T4-positive cells (helper cells) following intravenous immune serum globulin therapy; however, the percentages of the T cell subsets did not change significantly. Following immune serum globulin therapy, the number of T8-positive cells was not significantly changed but the T4:T8 ratio decreased from 2.1 at baseline to 1.5 after therapy (p greater than 0.05). These data demonstrate that long-term intravenous immune serum globulin administration modulates the immune system by increasing suppressor T cell functional activity but is not accompanied by changes in the number of T8-positive cells in the peripheral blood.
由于有证据表明短期给予混合供体γ球蛋白具有免疫调节作用，因此在两年时间里对9名患有常见变异型低丙种球蛋白血症的成年患者进行了静脉注射免疫血清球蛋白效果的研究。在进行免疫血清球蛋白替代治疗之前的基线评估包括对B细胞功能、抑制细胞活性和T细胞亚群的评估。随后在第一年静脉注射免疫血清球蛋白治疗期间（每月剂量为100至200mg/kg）以及第二年试验期间（每月剂量为300至400mg/kg）进行了这些分析。在第一个和第二个治疗期之间，有5名患者在停止静脉注射免疫血清球蛋白治疗4个月后接受了重新评估。在静脉注射免疫血清球蛋白的两个治疗期内，与基线相比，抑制细胞活性显著增加，并且在5名患者停止药物治疗后下降。通过对T细胞部分进行照射或通过流式细胞术去除T8阳性细胞部分，可以逆转抑制细胞活性。静脉注射免疫血清球蛋白治疗后，总淋巴细胞、T3阳性细胞（总T细胞）和T4阳性细胞（辅助细胞）的绝对数量减少；然而，T细胞亚群的百分比没有显著变化。免疫血清球蛋白治疗后，T8阳性细胞的数量没有显著变化，但T4:T8比值从基线时的2.1降至治疗后的1.5（p大于0.05）。这些数据表明，长期静脉注射免疫血清球蛋白通过增加抑制性T细胞功能活性来调节免疫系统，但外周血中T8阳性细胞的数量没有变化。
